Publications

Michels J, Venkatesh D, Liu C, Budhu S, Zhong H, George MM, Thach D, Yao Z-K, Ouerfelli O, Liu H et al..  2024.  APR-246 increases tumor antigenicity independent of p53.. Life Sci Alliance. 7(1)

Li J, Chin CR, Ying H-Y, Meydan C, Teater MR, Xia M, Farinha P, Takata K, Chu C-S, Jiang Y et al..  2024.  Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironment.. Nat Commun. 15(1):2879.

Kang JHye, Zappasodi R.  2023.  Modulating Treg stability to improve cancer immunotherapy.. Trends Cancer. 9(11):911-927.

Kluger H, J Barrett C, Gainor JF, Hamid O, Hurwitz M, LaVallee T, Moss RA, Zappasodi R, Sullivan RJ, Tawbi H et al..  2023.  Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors.. J Immunother Cancer. 11(3)

Davar D, Zappasodi R.  2023.  Targeting GITR in cancer immunotherapy - there is no perfect knowledge.. Oncotarget. 14:614-621.

Gregucci F, Spada S, Barcellos-Hoff MHelen, Bhardwaj N, Hak CChan Wah, Fiorentino A, Guha C, Guzman ML, Harrington K, Herrera FG et al..  2023.  Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference.. Oncoimmunology. 12(1):2222560.

Gigoux M, Holmström MO, Zappasodi R, Park JJ, Pourpe S, Bozkus CCimen, Mangarin LMB, Redmond D, Verma S, Schad S et al..  2022.  Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine.. Sci Transl Med. 14(649):eaba4380.

Huang AC, Zappasodi R.  2022.  A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance.. Nat Immunol. 23(5):660-670.

Zappasodi R, Cook GP, Taylor A.  2022.  Editorial: Factors determining long term anti-tumor responses to immune checkpoint blockade therapy.. Front Immunol. 13:1120207.

Schreier A, Zappasodi R, Serganova I, Brown KA, Demaria S, Andreopoulou E.  2022.  Facts and Perspectives: Implications of tumor glycolysis on immunotherapy response in triple negative breast cancer.. Front Oncol. 12:1061789.

Hoyos D, Zappasodi R, Schulze I, Sethna Z, de Andrade KCésar, Bajorin DF, Bandlamudi C, Callahan MK, Funt SA, Hadrup SR et al..  2022.  Fundamental immune-oncogenicity trade-offs define driver mutation fitness.. Nature. 606(7912):172-179.

Karasarides M, Cogdill AP, Robbins PB, Bowden M, Burton EM, Butterfield LH, Cesano A, Hammer C, Haymaker CL, Horak CE et al..  2022.  Hallmarks of Resistance to Immune-Checkpoint Inhibitors.. Cancer Immunol Res. 10(4):372-383.

Ghosh A, Michels J, Mezzadra R, Venkatesh D, Dong L, Gomez R, Samaan F, Ho Y-J, Campesato LFelipe, Mangarin L et al..  2022.  Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade.. J Clin Invest. 132(18)

Andrlová H, Miltiadous O, Kousa AI, Dai A, DeWolf S, Violante S, Park H-Y, Janaki-Raman S, Gardner R, Daker SEl et al..  2022.  MAIT and Vδ2 unconventional T cells are supported by a diverse intestinal microbiome and correlate with favorable patient outcome after allogeneic HCT.. Sci Transl Med. 14(646):eabj2829.

Davar D, Zappasodi R, Wang H, Naik GS, Sato T, Bauer T, Bajor D, Rixe O, Newman W, Qi J et al..  2022.  Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors.. Clin Cancer Res. 28(18):3990-4002.

He C, Maniyar RR, Avraham Y, Zappasodi R, Rusinova R, Newman W, Heath H, Wolchok JD, Dahan R, Merghoub T et al..  2022.  Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism.. Sci Adv. 8(8):eabm4552.

Schad SE, Chow A, Mangarin L, Pan H, Zhang J, Ceglia N, Caushi JX, Malandro N, Zappasodi R, Gigoux M et al..  2022.  Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions.. J Exp Med. 219(6)

Zappasodi R, Serganova I, Cohen IJ, Maeda M, Shindo M, Senbabaoglu Y, Watson MLJ, Leftin A, Maniyar R, Verma S et al..  2021.  CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours.. Nature. 591(7851):652-658.

Serganova I, Chakraborty S, Yamshon S, Isshiki Y, Bucktrout R, Melnick A, Béguelin W, Zappasodi R.  2021.  Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies.. Front Cell Dev Biol. 9:805195.

Fucà G, Ambrosini M, Agnelli L, Brich S, Sgambelluri F, Mortarini R, Pupa SM, Magni M, Devizzi L, Matteucci P et al..  2021.  Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells.. J Immunother Cancer. 9(6)

Alspach E, Chow RD, Demehri S, Guerriero JL, Gujar S, Hartmann FJ, Helmink BA, Hudson WH, Ho WJin, Ma L et al..  2021.  Supporting the Next Generation of Scientists to Lead Cancer Immunology Research.. Cancer Immunol Res. 9(11):1245-1251.

Budhu S, Giese R, Gupta A, Fitzgerald K, Zappasodi R, Schad S, Hirschhorn D, Campesato LFelipe, de Henau O, Gigoux M et al..  2021.  Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma.. Cell Rep. 34(2):108620.

Chakraborty S, Zappasodi R.  2021.  To Go or Not to Go?-Targeting Tregs Traveling in Tumors. Cancer Res. 81(11):2817-2819.

Xu S, Chaudhary O, Rodríguez-Morales P, Sun X, Chen D, Zappasodi R, Xu Z, Pinto AFM, Williams A, Schulze I et al..  2021.  Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors.. Immunity. 54(7):1561-1577.e7.

Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G et al..  2020.  B cells and tertiary lymphoid structures promote immunotherapy response.. Nature. 577(7791):549-555.